NextCell Pharma ABNXTCL 
$0.16-2.40%24h
-2.40%24h
Global rank34314
Market cap$5.49M
Change 7d5.16%
YTD Performance-38.02%
SP500 benchmarkUnderperform
P/E-0.14
P/S5.54
Revenue$990.69K
Earnings-$3.90M
Dividend yield-
Main Sector
Healthcare
Category
NextCell Pharma AB (NXTCL) Stock Overview
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden.
NXTCL Stock Information
Symbol
NXTCLAddress
Karolinska Institutet Science ParkHuddinge, 141 57Sweden
Founded
-Trading hours
-Website
https://www.nextcellpharma.comCountry
🇸🇪 SwedenPhone Number
46 87 35 55 95NextCell Pharma AB (NXTCL) Price Chart
-
Value:-
NextCell Pharma AB Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $0.15967086251653032 | N/A |
| Market Cap | $5.49M | N/A |
| Shares Outstanding | 34.38M | 0.00% |
| Employees | 17.00 | N/A |
| Shareholder Equity | 75.73M | -34.46% |
Valuation | 2023 | Change |
|---|---|---|
| P/E Ratio | -0.14 | N/A |
| P/S Ratio | 5.54 | N/A |
| P/B Ratio | 0.07 | N/A |
Growth | 2023 | Change |
|---|---|---|
| Return on Equity | -0.0515 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $990.69K | N/A |
| Earnings | -$3.90M | N/A |
| EPS | -1.16 | N/A |
| Earnings Yield | -7.25 | N/A |
| Gross Margin | -0.0875 | N/A |
| Operating Margin | -4.05 | N/A |
| Net income margin | -3.94 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $8.70M | N/A |
| Cash on Hand | $4.90M | N/A |
| Debt to Equity | 0.0169 | 119.24% |
| Current Ratio | $6.67 | -56.66% |
